Whiterabbit.ai
Whiterabbit.ai is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Whiterabbit.ai.
Whiterabbit.ai is a company.
Key people at Whiterabbit.ai.
Whiterabbit.ai is a healthcare technology company developing AI solutions to enhance breast cancer screening, focusing on earlier detection, improved radiologist accuracy, and better patient experiences.[1][2][3][5] It serves radiologists, healthcare providers, and patients by addressing key challenges like low screening compliance, radiologist shortages, and diagnostic errors through products such as WRDensity (FDA-cleared AI for breast density assessment) and WRRisk (risk assessment software for personalized screening).[5][7] The company has achieved growth momentum with over 2 million patients served, 11 million+ datapoints for AI training, partnerships with institutions like Stanford and Mallinckrodt Institute, and a team of 30+ AI specialists, scaling from stealth to commercial products.[2][5][6]
Whiterabbit.ai was founded in 2017 in the San Francisco Bay Area (initially Redwood City, later Santa Clara, California) by a team blending expertise in healthcare, medical imaging, software, and regulatory affairs.[3][6] Key leaders include CEO Alexander Sardiña, MD (20+ years in healthcare leadership) and CTO Jason Su (background in medical imaging and computer vision).[3] The idea emerged from recognizing AI's potential to tackle abundant breast cancer screening data for earlier detection, starting with AI-driven compliance tools and evolving through partnerships with top radiology providers and Washington University's Mallinckrodt Institute, which built robust datasets.[2][5][6] Pivotal moments include emerging from stealth in 2021 with a new CEO, FDA clearance for WRDensity, team growth to 82+ employees, and serving major mammography providers.[2]
Whiterabbit.ai stands out in AI-driven cancer screening through:
Whiterabbit.ai rides the AI in healthcare diagnostics wave, targeting breast cancer—a field with vast imaging data ripe for machine learning amid rising demand from aging populations and radiologist shortages.[3][5][6] Timing aligns with FDA's increasing AI clearances and post-pandemic screening backlogs, amplified by market forces like value-based care emphasizing outcomes and cost reduction.[5][7] It influences the ecosystem by validating AI's non-disruptive augmentation of radiologists (via Stanford studies), fostering data partnerships for better models, and scaling tools that improve 5-year survival rates through early detection.[2][6][7]
Whiterabbit.ai is poised for expansion with its commercially validated products, ongoing Stanford research, and roadmap toward broader cancer applications beyond breast screening.[5][7] Trends like multimodal AI (integrating images, records), personalized medicine, and global radiologist gaps will propel growth, potentially through more FDA nods and enterprise adoptions.[3][5] Its influence may evolve from niche mammography enhancer to ecosystem leader in early detection, reducing late-stage diagnoses if data moats and partnerships scale—echoing its core mission to eliminate suffering via precise, efficient AI.[1][4][6]
Key people at Whiterabbit.ai.
